Among them, GC/GG genotypes of the IL-6 promoter at position −174 (rs1800795) are associated with a better response to rituximab 6 months after the initial cycle, accompanied by a significant decrease in IL-6 serum levels in rheumatoid arthritis patients [80]. Here, IL6 is linked to rheumatoid arthritis.